Development of a simultaneous analytical method for five conjugated cholesterol metabolites in urine and investigation of their performance as diagnostic markers for Niemann-Pick disease type C.

Niemann-Pick disease type C (NPC) is an autosomal recessive disorder characterized by progressive nervous degeneration. Because of the diversity of clinical symptoms and onset age, the diagnosis of this disease is difficult. Therefore, biomarker tests have attracted significant attention for earlier diagnostics. In this study, we developed a simultaneous analysis method for five urinary conjugated cholesterol metabolites, which are potential diagnostic biomarkers for a rapid, convenient, and noninvasive chemical diagnosis, using liquid chromatography/tandem mass spectrometry (LC/MS/MS). By the method, their urinary concentrations were quantified and the NPC diagnostic performances were evaluated. The developed LC/MS/MS method showed high accuracy and and satisfied all analytical method validation criteria. Analyzing the urine of healthy controls and patients with NPC, three of five urinary conjugated cholesterol metabolites concentrations corrected by urinary creatinine were significantly higher in the patients with NPC. As a result of receiver operating characteristics analysis, the urinary metabolites might have excellent diagnostic marker performance. 3β-sulfooxy-7β-hydroxy-5-cholenoic acid showed particularly excellent diagnostic performance with both 100% clinical sensitivity and specificity, suggesting that it is a useful NPC diagnostic marker. The urinary conjugated cholesterol metabolites exhibited high NPC diagnostic marker performance and could be used for NPC diagnosis.

[1]  N. Mano,et al.  A Direct Injection LC/ESI-MS/MS Analysis of Urinary Cyclophosphamide as an Anticancer Drug for Monitoring Occupational Exposure , 2018 .

[2]  N. Mano,et al.  Identification of Two Sulfated Cholesterol Metabolites Found in the Urine of a Patient with Niemann-Pick Disease Type C as Novel Candidate Diagnostic Markers. , 2016, Mass spectrometry.

[3]  H. Runz,et al.  Development of a bile acid–based newborn screen for Niemann-Pick disease type C , 2016, Science Translational Medicine.

[4]  O. Morand,et al.  Plasma Lysosphingomyelin Demonstrates Great Potential as a Diagnostic Biomarker for Niemann-Pick Disease Type C in a Retrospective Study , 2014, PloS one.

[5]  C. Vite,et al.  Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease , 2010, Science Translational Medicine.

[6]  N. Mano,et al.  Chemical synthesis of 3β-sulfooxy-7β-hydroxy-24-nor-5-cholenoic acid: An internal standard for mass spectrometric analysis of the abnormal Δ5-bile acids occurring in Niemann-Pick disease , 2009, Steroids.

[7]  Joseph L. Goldstein,et al.  Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol , 2009, Cell.

[8]  J. Miners,et al.  Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase* , 2008, Journal of Biological Chemistry.

[9]  S. Miyata,et al.  Chemical synthesis of the 3-sulfooxy-7-N-acetylglucosaminyl-24-amidated conjugates of 3β,7β-dihydroxy-5-cholen-24-oic acid, and related compounds: Unusual, major metabolites of bile acid in a patient with Niemann-Pick disease type C1 , 2006, Steroids.

[10]  H. Ninomiya,et al.  [Niemann-Pick disease type C]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[11]  S. Steinberg,et al.  Complementation studies in Niemann-Pick disease type C indicate the existence of a second group. , 1994, Journal of medical genetics.

[12]  M. Polymeropoulos,et al.  Linkage of Niemann-Pick disease type C to human chromosome 18. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Edinburgh Research Explorer Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7 alpha-hydroxylase gene causes severe neonatal liver disease , 2022 .